Capricor Therapeutics Appoints New CFO, Leland J. Gershell, M.D., Ph.D.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) appointed  Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer.
According to the news:

Dr. Gershell brings to Capricor over 15 years of experience in the biotech sector, both within the industry and in finance as an equity research analyst and healthcare investor. He will report to Dr. Linda Marbán, Capricor’s Chief Executive Officer. His appointment is effective immediately.

Dr. Linda Marbán, Capricor’s Chief Executive Officer commented:

Leland’s experience in both the life sciences industry and on Wall Street is the ideal combination for Capricor.  He joins the team at an exciting time in our development as we have three active clinical programs investigating our cell therapy, CAP-1002, and are also investigating our naturietic peptide therapeutic Cenderitide. We also anticipate completing our preclinical development with our exosomes program this year. Over the past year, Capricor has focused on strengthening its management team to meet the needs of our growing therapeutic pipeline. Leland’s expertise will further enhance Capricor’s management team as it builds value for its investors.

Click here to view the full press release.